Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label extension study of AIN457 in Crohn's disease
2009-011621-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in Crohn's disease, sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of AIN457. Started Oct 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2009-011621-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011621-14.